BALA CYNWYD, Pa., Oct. 31, 2012 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Schiff Nutrition International, Inc. ("Schiff" or the "Company") (NYSE: SHF) relating to the proposed acquisition by Bayer AG ("Bayer").
Under the terms of the transaction, Schiff shareholders will receive only $34.00 in cash for each share on Schiff common stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Schiff for not acting in the Company's shareholders' best interests in connection with the sale process to Bayer. The transaction may undervalue the Company as Schiff announced that sales this fiscal year would increase by 40% to 43% after its acquisition of the cold- prevention remedy Airborne. In addition, the investigation also seeks to determine if conflicts of interests played a role in the transaction as Schiff's Board of Directors has agreed not to solicit any other competing offers.
If you own shares of Schiff stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at email@example.com visiting http://brodsky-smith.com/493-shf-schiff-nutrition-international-inc.html, by calling toll free 877-LEGAL-90.
Attorney Advertising. Past results do not guarantee a similar outcome.
SOURCE Brodsky & Smith, LLC